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Abstract 
Background: Recently, miR‑22 is identified as a tumor‑suppressing microRNA in many human cancers. CD147 is a 
novel cancer‑associated biomarker that plays an important role in the invasion and metastasis of malignant tumor. 
However, the involvement of miR‑22 in CD147 regulation and hepatocellular carcinoma (HCC) progression and 
metastasis has not been investigated.
Methods: We measured miR‑22 expression level in 34 paired of HCC and matched normal tissues, HCC cell lines by 
real‑time quantitative RT‑PCR. Invasion assay, MTT proliferation assay and wound‑healing assay were performed to 
test the invasion and proliferation of HCC cell after overexpression of miR‑22. The effect of miR‑22 on HCC in vivo was 
validated by murine xenograft model. The relationship of miR‑22 and its target gene CD147 was also investigated.
Results: We found that the expression of miR‑22 in HCC tissues and cell lines were much lower than that in normal 
control, respectively. The expression of miR‑22 was inversely correlated with HCC metastatic ability. Moreover, overex‑
pression of miR‑22 could significantly inhibit the HCC cell proliferation, migration and invasion in vitro and decrease 
HCC tumor growth in vivo. Finally, we found that miR‑22 interacted with CD147 and decreased its expression, via a 
specific target site within the CD147 3′UTR by luciferase reporter assay. The expression of CD147 was inversely cor‑
related with miR‑22 expression in HCC tissues.
Conclusion: Our results suggested that miR‑22 was downexpressed in HCC and inhibited HCC cell proliferation, 
migration and invasion through downregulating cancer‑associated gene CD147 which may provide a new bio‑target 
for HCC therapy.
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Background
Hepatocellular carcinoma (HCC) has become one of the 
most frequently occurring cancers, and is considered 
to be highly lethal, accounting for approximately one-
third of cancer-related deaths worldwide [1, 2]. Despite 
advances in the understanding of the molecular mecha-
nisms underlying HCC and improved treatments for 
HCC, the overall survival time is still limited [3].
Current studies have shown that microRNAs (miR-
NAs) can act as activators or inhibitors of tumor metas-
tasis by targeting multiple signaling pathways involved in 
metastasis [4–6]. miR-22 is a 22-nt non-coding RNA and 
originally identified in HeLa cells as a tumor-suppressing 
miRNA. Subsequently, miR-22 was identified to be ubiq-
uitously expressed in a variety of tissues [7]. Recently, 
several targets of miR-22 were reported to mediate its 
tumorsuppressive effect, such as tumor-suppressive 
PTEN, Max genes, p21, Sp1, CD147 and oncogene c-myc 
expression, etc. [7–11].
CD147 which is a 58-kDa transmembrane glycopro-
tein belonging to the immunoglobulin superfamily [12, 
13] is highly expressed in many tumors, including breast 
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cancer, lymphoma, oral squamous cell carcinoma, gli-
oma, melanoma, lung, bladder, liver and kidney carci-
nomas [13–15]. It has been demonstrated that CD147 
contributes significantly to tumor growth, metastasis and 
angiogenesis through stimulating the production of hya-
luronan, multiple matrix metalloproteinases (MMPs) and 
vascular endothelial growth factor A (VEGF-A) [16]. It 
has been reported that miR-22 inhibits cell migration and 
invasion through targeting CD147 in breast cancer [11]. 
So we want to explore whether there exists this relation-
ship of miR-22 and CD147 in the HCC progression.
In the current study, we validate the differential expression 
of miR-22 in HCC and investigated the function of miR-22 
in migration and invasion of HCC cells. Furthermore, we 
identified CD147 as a target gene for miR-22 to regulate the 
invasion and metastasis of HCC cells in vitro. miR-22 might 
act as a tumor suppressor and serve as a potential therapeu-
tic target in HCC. To the best of our knowledge, this is the 
first study to examine the regulation mechanism of miR-22 
and CD147 in HCC migration and invasion.
Methods
HCC tissue specimens and immunohistochemical analysis
Thirty-four paired tissue specimens of HCC and adjacent 
non-tumor (ANT) tissues were obtained from Depart-
ment of Hepatobiliary Surgery, Affiliated Traditional 
Chinese Medicine Hospital, Xinjiang Medical University. 
Informed consent was obtained from each patient. The 
thirty-four HCC tissues were divided into two groups: 
metastatic HCC tissues (patients with lung metastasis or 
portal vein cancer embolus, n = 20) and non-metastatic 
HCC tissues (n  =  14). All of the tissues were obtained 
at the time of surgery and immediately stored in liquid 
nitrogen until use.
Immunohistochemistry was performed using Histo-
stain-SP kits (Invitrogen, Carlsbad, CA, USA) according 
to the manufacturer’s instructions. Antibodies were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). Immunopositivity was independently evaluated by 
two pathologists. Expression of protein was evaluated as 
described previously [17, 18].
Cell lines and culture conditions
The following cell lines were used in this study: human 
normal liver cell QZG [19], QSG-7701 [20] and HL-7702 
[21]; human hepatocellular carcinoma cell lines: HepG2, 
BEL-7402, FHCC-98, SMMC-7721, HCC-9724, MHCC-
97H (HCC cells with high metastatic potential) and 
MHCC-97L (HCC cells with low metastatic potential) 
[22]. All cell lines were purchased from Shanghai Insti-
tute for Biological Sciences (Shanghai, China). All cell 
lines were routinely cultured in RPMI-1640 medium 
(Hyclone Laboratories, Logan, UT) supplemented with 
10% fetal calf serum (Gibco BRL, Rockville, MD, USA) at 
37 °C in a humidified atmosphere of 5% CO2.
RNA extraction and real‑time quantitative RT‑PCR
Total RNA was isolated from tissues and cell lines by using 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions. Reverse transcrip-
tion was performed using the Prime-Script RT reagent 
kit (TaKaRa, Otsu, Japan). The glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) mRNA and U6 small 
nuclear RNA were used as internal controls, respectively. 
All of the reactions were run in triplicate. Forward and 
reverse primers for miR-22, u6 snRNA, were 5′-AAGCT-
GCCAGTTGAAGAACTGTA-3′ and Universal Primer 
(Qiagen, Hilden, Germany), 5′-CTCGCTTCGGCAG-
CACA-3′ and 5′-AACGCTTCACGAATTTGCGT-3′, 
respectively. The primers for CD147 and GAPDH 
mRNA were 5′-TCGCGCTGCTGGGCACC-3′ and 
5′-TGGCGCTGTCATTCAAGGA-3′, 5′-GGTCG-
GAGTCAACGGATTTG-3′ and 5′-ATGAGCCCCAGC-
CTTCTCCAT-3′, respectively. The relative expression 
levels were evaluated using the ΔΔCt method [15, 23].
Plasmid construction and luciferase activity assay
The miR-22 overexpression vector was constructed 
according to previous [24] named as pcDNA3.1-miR-22. 
The full-length and mutant construct of CD147 3′-UTR 
were amplified [11]. Pooled multiple siRNAs targeting 
CD147 [25] were synthesized by Genepharma (Shang-
hai, China). All constructs were further confirmed by 
sequencing. Cell transfection and dual luciferase reporter 
assay were performed as described previously [26].
Cell proliferation assay
Cells were plated in sixduplicate in 96-well plates (2 × 103 
per well) in 100  μL complete medium and allowed to 
attach overnight. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphe-
nyl-2H-tetrazolium bromide (MTT) (20 μL at 5 mg/mL; 
Sigma, St. Louis, MO) was added every 24  h and incu-
bated for 4 h. The supernatant was discarded, the precipi-
tate was dissolved in 200 μL dimethyl sulfoxide (DMSO), 
and plates were read with a microplate reader at 570 nm 
[27].
Wound‑healing assay
1  ×  106 cells were seeded in six-well plates, cultured 
overnight, and transfected with miR-22 overexpression 
vector or NC, respectively. When the culture had reached 
nearly 90% confluency, the cell layer was scratched with a 
sterile plastic tip and then washed with culture medium 
twice and cultured again for up to 48 or 72 h with serum-
reduced medium containing 1% FBS. At different time 
points, photographic images of the plates were acquired 
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under a microscope and the data were summarized based 
on sextuple assays for each experiment.
In vitro invasion and migration assay
MilliCell (12  mm diameter with 8  µm pores) chambers 
(Millipore, Bedford, MA, USA) were pre-coated with 
Matrigel (BD, Bedford, MA, USA) on the upper side. A 
total of 1 × 105 serum-starved HCC cells were added to 
the upper compartment in medium supplemented with 
0.1% serum, and the chambers were placed into 24-well 
plates with medium containing 10% serum. After 24 h at 
37 °C, invaded cells on the lower membrane surface were 
fixed and stained with 0.1% crystal violet. Invasive activ-
ity was quantified by counting nine high-power fields 
(HPFs, 400×) per chamber. Mean values were obtained 
from at least three individual chambers for each experi-
mental point per assay. The migration assay is the same 
with invasion assay excepting no matrigel was used and 
the permeating time for cells was 12 h.
In vivo proliferation assay
BALB/c nude mice at 4–6 weeks of age were provided by 
the Laboratory Animal Research Center of Xinjiang Medi-
cal University, and the animal study was reviewed and 
approved by the Xinjiang Medical University Animal Care 
and Use Committee. A total of 1 × 107 MHCC-97H cells 
stably expressing miR-22 were injected subcutaneously into 
nude mice. 60  days after injection, the mice were killed. 
Tumor volume was determined using direct measurement 
and calculated using the formula length × width2/2.
Western blot analysis
Cell samples were lysed with RIPA buffer (Beyotime, 
China). Equal amounts (10  μg) of total protein were 
loaded, and then subsequently immunoblotted with the 
primary antibodies, including anti-CD147 and tubulin 
monoclonal antibodies (Santa Cruz, CA, USA). Proteins 
were detected using the Amersham enhanced chemilu-
minescence system (Pierce, Rockford, IL, USA) according 
to the manufacturer’s instructions.
Statistical analysis
All statistical analyses were performed using the SPSS 
16.0 statistical software package (SPSS, Chicago, IL, 
USA). The significance of the data was determined using 
Student’s t test. All the statistical tests were two-sided, 
and a P < 0.05 was considered significant.
Results
The expression of miR‑22 is downexpressed in HCC tissues 
and cell lines
To identify the expression of miR-22 in the HCC, thirty-
four paired of HCC and normal tissues were measured by 
real time RT-PCR. As shown in Fig. 1a, miR-22 expres-
sion levels were downexpressed in HCC tissues com-
pared with ANT tissues (P  <  0.05). Furthermore, the 
expression of miR-22 in metastatic HCC tissues was 
much lower than in no metastatic HCC tissues (Fig. 1a) 
which indicated that the miR-22 expression was nega-
tively correlated with the HCC metastatic ability.
The miR-22 expression in HCC and normal liver cell 
lines were also detected. We performed real-time RT-
PCR on a panel of seven HCC and three normal liver cell 
lines. And miR-22 expression of each cell line was com-
pared to the average expression level of miR-22 of three 
normal liver cell lines. As shown in Fig. 1b, miR-22 lev-
els of all cell lines were lower than that of normal liver 
cell lines. miR-22 expression in MHCC-97H, FHCC-98 
and SMMC-7721 cells was relatively low. In contrast, 
expression levels of miR-22 in HepG2 and MHCC-97L 
Fig. 1 miR‑22 is down‑expressed in HCC tissues and cell lines. a Analysis of the expression pattern of miR‑22 in non‑metastasis tumors and metas‑
tasis tumors of HCC correlated with adjacent non‑tumor tissues using real‑time RT‑PCR. b The relative levels of miR‑22 in the seven HCC and three 
normal liver cell lines. Student’s t test was used to analyze the significant differences, *P < 0.05, **P < 0.01
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cells were relatively high. The lower expression of miR-
22 in HCC cells with low metastatic potential suggested 
a causal role for miR-22 in the migration and invasion of 
HCC cell lines.
miR‑22 inhibits HCC cell proliferation, migration 
and invasion in vitro and decreases HCC tumor growth 
in vivo
To investigate whether miR-22 regulates HCC cell migra-
tion and invasion, we selected MHCC-97H cells and 
SMMC-7721 which show strong migration and invasion 
potential for further study. First, we performed gain-of-
function analysis and transfected miR-22 overexpres-
sion vector into MHCC-97H and SMMC-7721 cells to 
increase miR-22 expression. As expected, transfection 
of miR-22 overexpression vector resulted in substantial 
increase of miR-22 expression compared with pcDNA3.1 
control transfected cells (Fig. 2a).
Then, we performed MTT cell proliferation assays with 
transfected miR-22 overexpression in MHCC-97H and 
SMMC-7721 cells. Our results showed that overexpres-
sion of miR-22 could significantly suppress HCC cell 
proliferation (P < 0.05, Fig. 2b). Next, the wound-healing 
assay showed that HCC cells with miR-22 overexpression 
presented a slower closing of scratch wound, compared 
with the negative controls (P < 0.05, Fig. 2c). Moreover, 
the cell migration and invasion assay showed that over-
expression of miR-22 resulted in reduced migration rate 
and invasion rate of MHCC-97H and SMMC-7721 cells 
compared with the control (Fig. 2d). Our results indicate 
that miR-22 worked as a tumor suppressor microRNA 
and contributed to inhibit HCC cells migration and inva-
sion in vitro.
We next asked whether miR-22 could inhibit HCC 
development in  vivo. Using HCC tumor models, the 
control mice showed the apparent presence of primary 
Fig. 2 Overexpression of miR‑22 inhibited HCC cell proliferation and metastasis in vitro. a Transfection of miR‑22 overexpression vector to MHCC‑
97H and SMMC‑7721 cells increases the expression of miR‑22 detected by real‑time quantitative RT‑PCR. b Cell proliferation of these cells trans‑
fected as in a was measured at the indicated time periods using the MTT assay. c Overexpression of miR‑22 presented a slower closing of scratch 
wound, compared with pcDNA3.1 control, at 48 h after transfection in MHCC‑97H and SMMC‑7721 cells. d Migration and invasion potential in both 
cell lines treated as above were measured by Transwell assays and were expressed as relative cell numbers. Scale bars, 50 μm. Scale bars, 50 μm. 
*P < 0.05
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tumor, whereas those injected with miR-22 expression 
vector decreased the volume and weight of tumors dur-
ing the same observation period (Fig.  3). Judging from 
data between the controls and miR-22-treated groups at 
the points of the experiment, miR-22 treatment resulted 
in a mean of decreasing in tumor growth.
miR‑22 negatively regulates CD147 gene expression
It has been reported that miR-22 could regulate CD147 
expression in breast cancer [11]. So we want to explore 
whether there exists this relationship of miR-22 and 
CD147 in the HCC progression. To confirm that CD147 
is a target gene for miR-22, real time RT-PCR and west-
ern blot analysis were used to detect the expression of 
CD147 after transfected with miR-22 overexpression 
vector in MHCC-97H and SMMC-7721. The expression 
of CD147 was significantly down-regulated after over 
expression of miR-22 at the mRNA level (Fig. 4a) and the 
protein level (Fig.  4b) compared with negative control, 
respectively.
Furthermore, we also detected the CD147 expression 
in thirty-four pairs of HCC and normal tissues by immu-
nohistochemistry. CD147 was predominantly localized to 
the cytoplasm and membrane and the positive expression 
rate of CD147 was much higher in HCC (24/34) than that 
in ANT (11/34) (Fig.  4c). Correlation analysis indicated 
that there was a significant inverse correlation between 
the miR-22 mRNA and CD147 protein expression with 
a correlation coefficient (r) = −0.6684 and R2 =  0.4467 
(Fig.  4d). This correlation indicates that miR-22 could 
negatively regulateCD147 expression in HCC tissues. 
Taken together, our results suggest that miR-22 nega-
tively regulates CD147 gene expression and that CD147 
is a potential target gene of miR-22.
CD147 is a direct target of miR‑22
To verify whether miR-22 directly targeted CD147 in 
HCC cell lines, luciferase reporter assays were con-
ducted. We constructed pmirGLO-CD147-3′-UTR and 
pmirGLO-CD147-3′-UTR-mut with a substitution of 
four nucleotides within the miR-22 binding site (Fig. 5a). 
Cotransfection of MHCC-97H cells with pmirGLO-
CD147-3′-UTR and miR-22/pcDNA3.1 caused a 59.3% 
decrease in the luciferase activity compared with the 
negative control (P < 0.05). This suppression was rescued 
by the four-nucleotide substitution in the core bind-
ing sites (Fig.  5b). The similar effect was also found in 
SMMC-7721 cells (68.3% decrease compared to the blank 
Fig. 3 miR‑22 decreases HCC growth in vivo. a Representative figures of tumors in negative control and miR‑22 overexpression groups. b Determi‑
nation of tumor volumes at different time points. c After the final measure, the mice were sacrificed, and the tumors were excised. Tumor volume 
was measured and calculated using the formula length × width2/2. Student’s t test was used to analyze the significant differences
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control, P  <  0.05, Fig.  5b). These results indicated that 
miR-22 served as a tumor metastasis suppressor in HCC 
cell through the CD147 pathway.
Discussion
Hepatocellular carcinoma is one of the most frequently 
occurring cancers with poor prognosis. Before the age of 
60 years, HCC is the most commonly diagnosed cancer 
and the leading cause of cancer death in men [28]. But 
novel diagnostic or prognostic biomarkers and thera-
peutic targets for HCC are urgently required. With the 
advance of high-resolution microarrays and massively 
parallel sequencing technology, miRNAs are suggested to 
play critical roles in the tumorigenesis and development 
of human HCC.
miRNAs have been demonstrated to have close rela-
tionship with HCC. miR-22, originally identified in HeLa 
cells, has been found to be overexpressed in prostate can-
cer, but down-regulated in breast cancer, cholangiocarci-
noma, multiple myeloma, and hepatocellular carcinoma 
[27]. miR-22 inhibits cell growth and induces cell-cycle 
arrest, apoptosis and senescence in breast cancer, colon 
cancer and lung cancer [29]. miR-22 plays a tumor-sup-
pressive role by downregulating oncogenic target genes 
in many kinds of cancer [10, 24, 30, 31]. However, on 
the other side, miR-22 was recently suggested having 
an oncogenic role by targeting PTEN or TET family [8, 
32]. The reported paradoxical functions of miR-22 imply 
that miR-22 might act as a tissue/cell-specific or context-
dependent tumor suppressor microRNA and the func-
tion diversely depending on its target genes and related 
regulatory networks. Perhaps, miR-22 may play more 
complex roles that exceed our perception in cancer, 
which needs us to explore it more deeply.
In this study, we demonstrated that miR-22 expres-
sion was decreased in HCC tissues and cell lines com-
pared detected by real– time RT– PCR. Furthermore, 
the expression of miR-22 in metastatic HCC tissues was 
much lower than in no metastatic HCC tissues which 
indicated that the miR-22 expression was correlated 
with the HCC metastatic ability. Overexpression of miR-
22 in MHCC-97H and SMMC-7721 cells significantly 
inhibited cellular proliferation, migration and invasion 
capability in  vitro. In the HCC tumor models, miR-22 
expression vector decreased the HCC tumors growth. 
Taken together, our results suggest that miR-22 worked 
as a tumor suppressor miRNA and contributed to inhibit 
HCC cells migration and invasion in vitro.
Previous work showed that CD147 was more strongly 
upregulated in HCC specimens than in the adjacent tis-
sues and that this overexpression correlated with tumor 
metastasis and advanced histologic grades [14, 33–35]. In 
Fig. 4 miR‑22 negatively regulates CD147 gene expression. miR‑22 inhibited the expression of CD147 at the mRNA level a and the protein level b 
in MHCC‑97H and SMMC‑7721 cells. c IHC analysis of CD147 protein expression in HCC and paired adjacent normal tissues. Pictures of representa‑
tive areas are presented at different staining intensities (weak and strong) in ANT and tumor tissues. Scale bars, 50 μm. d Analysis for correlation of 
miR‑22 mRNA and CD147 protein expression in HCC tissues
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the present study, we found an inverse correlation between 
miR-22 and CD147 expression in the HCC tissues. Our 
results are also shown that CD147 is negatively regulated 
by miR-22 at the posttranscriptional level, via a specific tar-
get site within the 3′UTR. miR-22 inhibits HCC cell migra-
tion and invasion through the CD147 pathway. Hence, our 
work indicates that miR-22 is an important suppressor in 
HCC invasion and metastasis, and CD147 seems to be a 
major downstream effector of miR-22 in its target network. 
Currently, the emergence of new technologies that use syn-
thetic miRNA mimics or anti–miRNA oligonucleotides 
holds great promise for clinical miRNA therapy [36]. Syn-
thetic miR-22 mimic treatments for cancer will become a 
significant scientific and therapeutic challenge.
In conclusion, miR-22 down-expressed in HCC and the 
overexpression of miR-22 inhibited cell migration and 
invasion of HCC cells in vitro, and decrease HCC tumor 
growth in vivo. CD147 contains the binding site for miR-
22 and is negatively regulated by miR-22. Down-regu-
lation of CD147 mediated miR-22 function. This newly 
identified miR-22/CD147 link provides a new, potential 
therapeutic target to treat HCC.
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Fig. 5 The CD147 3′UTR is a target of miR‑22. a Diagram of the luciferase reporter plasmids: plasmid with the full length CD147 3′UTR insert and 
plasmid with a mutant CD147 3′UTR which carried a substitution of four nucleotides within the miR‑22 binding site. b The relative luciferase activity 
in MHCC‑97H and SMMC‑7721 cells were determined after the CD147 3′UTR or mutant plasmids were co‑transfected with miR‑22 overexpression 
vector or negative control
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